IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection for Advanced Cancers

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Advanced Cancers+1 MoreIBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer drug to see if it is safe and works better than current treatments.

Eligible Conditions
  • Advanced Cancers
  • Advanced Malignant Lymphomas

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
JTX-8064
1
HB0025
1
SRK-181

Study Objectives

4 Primary · 7 Secondary · Reporting Duration: Through study completion, an average of 1 year

Day 21
Dose Limiting Toxicity (DLT)
28 days
Number of DLT time
Day 90
Number of treatment related AEs
Day 90
Treatment-related Adverse Events (TRAEs)
Year 1
Positive rate of Circulating Immune Complex
Day 90
PK parameters
PK parameters: Maximum concentration (Cmax)
PK parameters: The area under the curve (AUC)
PK parameters: The half-life (t1/2)
PK parameters: Time at which maximum concentration (Tmax)
Positive rate of ADA and Nab

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
JTX-8064
1
HB0025
1
SRK-181

Trial Design

1 Treatment Group

Dose Escalation of IBI322
1 of 1

Experimental Treatment

51 Total Participants · 1 Treatment Group

Primary Treatment: IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection · No Placebo Group · Phase 1

Dose Escalation of IBI322
Biological
Experimental Group · 1 Intervention: IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year

Who is running the clinical trial?

Innovent Biologics (Suzhou) Co. Ltd.Lead Sponsor
133 Previous Clinical Trials
21,989 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a performance status of 0 or 1.
You are a male or female > 18 years old.
Female subjects of childbearing age or male subjects whose partners are women at childbearing age, need to use 2 highly effective contraceptive measures, including one barrier method, throughout the treatment period and 6 months after the treatment period.
You are willing to sign an informed consent form and be able to comply with the study's rules and visits/related procedures.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top